| Literature DB >> 30944812 |
Xiang-Chun Ding1, Wan-Long Ma1, Ming-Kun Li2, Shuai-Wei Liu1, Xiao-Yan Liu1, Long Hai1, Xia Luo1, Yan-Chao Hu1, Li-Na Ma1.
Abstract
Background and Aims: Studies have indicated that serum von Willebrand factor (vWF) has a positive correlation with hepatic venous pressure gradient. However, information on the value of vWF in the diagnosis of liver cirrhosis with portal hypertension has been lacking. The purpose of this meta-analysis was to assess the value of vWF in the diagnosis of liver cirrhosis with portal hypertension.Entities:
Keywords: HVPG; Liver cirrhosis; Portal hypertension; vWF
Year: 2018 PMID: 30944812 PMCID: PMC6441641 DOI: 10.14218/JCTH.2018.00036
Source DB: PubMed Journal: J Clin Transl Hepatol ISSN: 2225-0719
The serum levels of vWF in the included studies
| vWF | Cirrhosis without portal hypertension (HVPG<10 mmHg) | Cirrhosis with portal hypertension (HVPG≥10 mmHg) | Cutoff |
| Monika Ferlitsch | 197% (158%–228%) | 346% (275%–441%) | 241% |
| Stephanie Hametner | 200% (157%–236%) | 306% (227%–373%) | 226% |
| M. Homonclik | 210% (176%–243%) | 355% (322%–388%) | 264% |
| Hao Wu | 1240±470.3 mU/mL | 2430±760.3 mU/mL | 1510.5 mU/mL (231%) |
Fig. 1.Literature search flow sheet.
The basic information of the literature included
| Study | Monika Ferlitsch | Stephanie Hametner | Hao Wu | M. Homonclik |
| Year of publication | 2012 | 2016 | 2015 | 2017 |
| Sample size | 286 | 236 | 60 | 81 |
| Male/Female | 201/65 | 170/66 | 43/17 | 67/14 |
| Age | 55 (48–62) | 57.9 (50–60) | 49 (45–52) | 54 |
| Etiology | – | ALD 93; HCV 67; NASH 29; other 19; unknown 28 | HBV | ALD, HCV, cryptogenic |
| CPS (A/B/C) | 48/104/34 | 140/56/18 | 28/19/13 | – |
| Compensation | 189 | 136 | – | – |
| Decompensation | 97 | 100 | – | – |
Quality assessment
| Study | Monika Ferlitsch | Stephanie Hametner | Hao Wu | M. Homonclik |
| Was the spectrum of patients representative of the patients who will receive the test in practice? | Yes | Yes | Yes | Yes |
| Were selection criteria clearly described? | Yes | Yes | Yes | Yes |
| Is the reference standard likely to correctly classify the target condition? | Yes | Yes | Yes | Yes |
| Did patients receive the same reference standard regardless of the index test result? | Yes | Yes | Yes | Yes |
| Was the reference standard independent of the index test? | Yes | Yes | Yes | Yes |
| Were the reference standard results interpreted without knowledge of the results of the index test? | Yes | Yes | Yes | Yes |
| Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? | Yes | Yes | Yes | Yes |
| Were withdrawals from the study explained? | Yes | Yes | Yes | Yes |
| Were the index test results interpreted without knowledge of the results of the reference standard? | No | No | No | No |
| Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests? | Yes | Yes | Unclear | Unclear |
| Did the whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis? | Yes | Yes | Yes | Yes |
| Was the execution of the index test described in sufficient detail to permit replication of the test? | Yes | Yes | Yes | No |
| Was the execution of the reference standard described in sufficient detail to permit its replication? | Yes | Yes | Yes | No |
| Were uninterpretable/ intermediate test results reported? | Yes | Yes | Yes | No |
Fig. 2.Forest map of the meta-analysis.
Fig. 3.Forest map of diagnostic odds ratio.
Fig. 4.Summary receiver operating characteristic curve.